April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

March 14, 2025

HPV Vaccine Reduces Actinic Keratoses

VAXAK randomized trial demonstrates significant reduction in precancerous skin lesions following standard 9-valent alphapapillomavirus vaccination.

Conexiant

March 06, 2025

COVID-19 Increases Autoimmune Blistering Disease Risk, Study Finds

COVID-19 infection significantly increases autoimmune blistering disease risk, while vaccination appears protective, researchers report in a study analyzing 112 million patient records

Conexiant

December 16, 2024

FDA Approves Unloxcyt for Skin Cancer

FDA approves Unloxcyt, a new drug by Checkpoint Therapeutics, for the treatment of advanced and metastatic cutaneous squamous cell carcinoma, showing promising results in clinical studies.

Reuters

October 11, 2024

Skin Pigmentation: Rethinking Drug Efficacy

With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.

Conexiant

February 28, 2025

New Study Backs Mohs Surgery for High-Risk cSCC

Mohs surgery was associated with improved outcomes in the treatment of primary high-stage cSCC compared with WLE.

Conexiant